目的：探讨复方血栓通胶囊联合羟苯磺酸钙治疗非增生性糖尿病性视网膜病变(diabetic retinopathy，DR)患者的疗效。

方法：选取120例非增生性DR患者，按照随机数字表法分为研究组和对照组，各60例。对照组患者治疗采用复方血栓通胶囊，研究组患者采用复方血栓通胶囊联合羟苯磺酸钙治疗。观察并比较两组患者治疗前后的临床症状(血管瘤体积、出血斑面积、黄斑厚度、视野灰度值、视力、30°内阈值敏感程度)、炎症因子指标(血清hs-CRP、VEGF、IGF-1)、临床疗效及不良反应发生情况。

结果：(1)两组患者治疗5mo，血管瘤体积、出血斑面积、黄斑厚度、视野灰度值均低于治疗前(t_研究组=24.81、19.59、8.567、17.79，t_对照组=12.02、8.60、10.32，10.85，P<0.05)，视力、30°内阈值敏感程度均优于治疗前(t_研究组=-5.24、-8.79，t_对照组=-2.26、-3.39，P<0.05)； 研究组患者的血管瘤体积、出血斑面积、黄斑厚度、视野灰度值均低于对照组，视力、30°内阈值敏感程度均优于对照组，差异均具有统计学意义(t=-12.97、-9.47、-13.54、-5.59、2.65、4.05，P<0.05)。(2)两组患者治疗5mo，血清hs-CRP、VEGF、IGF-1水平均低于治疗前(t_研究组=34.30、23.33、42.118，t_对照组=18.68、17.46、26.73，P<0.05)； 研究组的hs-CRP、VEGF、IGF-1水平均低于对照组，差异均具有统计学意义(t=-14.79、-7.43、-15.35，P<0.05)。(3)研究组临床治疗总有效率为92.0%，高于对照组的70.8%，差异具有统计学意义(χ²=16.352，P<0.05)。(4)研究组患者不良反应总发生率为10%，对照组为13%，两组患者不良反应发生率的差异无统计学意义(χ²=0.32，P>0.05)。

结论：复方血栓通胶囊联合羟苯磺酸钙治疗非增生性DR，能有效改善患者的临床症状，其作用机制与血清炎症因子水平相关，临床疗效较好，安全性高。

METHODS: Totally 120 patients with early diabetic retinopathy were selected, and they were randomly divided into study group and control group according to the random number table method, each had 60 cases. Patients in the control group were treated with compound Xueshuantong capsule, and the patients in the study group were treated with compound Xueshuantong capsule combined with calcium dobesilate. We observed and compared the clinical symptoms(hemangioma volume, hemorrhagic spot area, macular thickness, visual gray value, visual acuity, threshold sensitivity within 30°), inflammatory factors(serum hs-CRP, VEGF, IGF-1), clinical efficacy and adverse events.

RESULTS:(1)The hematoma volume, hemorrhage spot area, macular thickness and visual gray value of the two groups were lower than those before treatment(t_{study group}=24.81, 19.59, 8.567, 17.79, t_{control group}=12.02, 8.60, 10.32, 10.85; P<0.05); visual acuity, threshold sensitivity within 30°were significantly higher than before(t_{study group}=-5.24, -8.79, t_{study group}=-2.26, -3.39; all P<0.05). After treatment, hemangioma volume, haemorrhagic area, macular thickness and visual gray value of the study group were lower than those of the control group, visual acuity and threshold sensitivity within 30°were higher than those of the control group(t=-12.97, -9.47,-13.54, -5.59, 2.65, 4.05; all P<0.05).(2)The levels of hs-CRP, VEGF and IGF-1 in the two groups were lower than those before treatment(t_{study group}=34.30, 23.33, 42.118, t_{control group} =18.68, 17.46, 26.73; all P<0.05). The levels of hs-CRP, VEGF and IGF-1 in the study group were significantly lower than those in the control group(t=-14.79, -7.43, -15.35, all P<0.05).(3)The total effective rate was 92.0% in the study group, which was higher than 70.8% in the control group(χ²=16.352, P<0.05).(4)The incidence of adverse reactions was 10% in the study group and 13% in the control group. There was no significant difference in the incidence of adverse reactions between the two groups(χ²=0.32, P>0.05).

CONCLUSION: Compound Xueshuantong capsule combined with calcium dobesilate in the treatment of early diabetic retinopathy can effectively improve the clinical symptoms of retinal defects, the mechanism of action is related to the level of inflammatory factors, the clinical efficacy is better, security is high.